Yong-Seok Heo Selected Research

Neoplastic Cell Transformation

3/2016	Bakuchiol suppresses proliferation of skin cancer cells by directly targeting Hck, Blk, and p38 MAP kinase.
6/2011	Coffee phenolic phytochemicals suppress colon cancer metastasis by targeting MEK and TOPK.
4/2011	Isorhamnetin suppresses skin cancer through direct inhibition of MEK1 and PI3-K.
8/2010	Phosphatidylinositol 3-kinase, a novel target molecule for the inhibitory effects of kaempferol on neoplastic cell transformation.
2/2009	MKK4 is a novel target for the inhibition of tumor necrosis factor-alpha-induced vascular endothelial growth factor expression by myricetin.
11/2007	Equol, a metabolite of the soybean isoflavone daidzein, inhibits neoplastic cell transformation by targeting the MEK/ERK/p90RSK/activator protein-1 pathway.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Yong-Seok Heo Research Topics

Disease

21	Neoplasms (Cancer) 03/2022 - 01/2005
9	Skin Neoplasms (Skin Cancer) 03/2016 - 07/2008
8	Inflammation (Inflammations) 11/2017 - 09/2003
7	Carcinogenesis 09/2011 - 07/2008
6	Obesity 01/2019 - 01/2005
6	Neoplastic Cell Transformation 03/2016 - 11/2007
3	Neoplasm Metastasis (Metastasis) 10/2013 - 06/2011
2	Rheumatoid Arthritis 03/2018 - 01/2017
1	Communicable Diseases (Infectious Diseases) 03/2022
1	Immune System Diseases (Immune Disorders) 03/2022
1	Endometrial Neoplasms (Endometrial Cancer) 01/2022
1	Multiple Myeloma 01/2021
1	acquired Thrombotic thrombocytopenic purpura 01/2021
1	Hodgkin Disease (Hodgkin's Disease) 01/2020
1	Weight Gain 01/2019
1	Psoriatic Arthritis 03/2018
1	Crohn Disease (Crohn's Disease) 03/2018
1	Systemic Lupus Erythematosus (Libman-Sacks Disease) 01/2018
1	Autoimmune Diseases (Autoimmune Disease) 01/2017
1	Inflammatory Bowel Diseases (Inflammatory Bowel Disease) 01/2017
1	Premature Ejaculation 03/2016
1	Carcinoma (Carcinomatosis) 03/2016
1	Back Pain (Backache) 03/2016
1	Psoriasis (Pustulosis Palmaris et Plantaris) 03/2016
1	Alopecia (Baldness) 03/2016
1	Pain (Aches) 03/2016
1	Enuresis 03/2016
1	Vitiligo 03/2016
1	Uterine Cervical Neoplasms (Cancer of the Cervix) 08/2014
1	Occupational Stress 12/2013
1	Colorectal Neoplasms (Colorectal Cancer) 10/2013
1	Chronic Disease (Chronic Diseases) 01/2013

Drug/Important Bio-Agent (IBA)

7	Monoclonal AntibodiesIBA 01/2022 - 10/2016
5	IsoflavonesIBA 01/2019 - 11/2007
5	Cyclooxygenase 2 (Cyclooxygenase-2)IBA 09/2011 - 02/2009
4	Proteins (Proteins, Gene)FDA Link 01/2021 - 01/2005
4	Phosphotransferases (Kinase)IBA 11/2017 - 02/2009
3	Pharmaceutical PreparationsIBA 01/2021 - 09/2003
3	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 01/2017 - 04/2009
3	Epidermal Growth Factor (EGF)IBA 03/2016 - 07/2010
3	PhytochemicalsIBA 10/2013 - 04/2010
2	LigandsIBA 01/2022 - 01/2020
2	AntibodiesIBA 01/2020 - 10/2016
2	durvalumabIBA 03/2019 - 01/2017
2	atezolizumabIBA 03/2019 - 01/2017
2	avelumabIBA 03/2019 - 01/2017
2	GenisteinIBA 01/2019 - 04/2011
2	EpitopesIBA 10/2016 - 01/2008
2	Biological ProductsIBA 12/2013 - 04/2011
2	ResveratrolIBA 10/2013 - 03/2012
2	3,3',4,5'-tetrahydroxystilbeneIBA 10/2013 - 03/2012
2	Matrix Metalloproteinases (MMPs)IBA 10/2013 - 10/2013
2	LuteolinIBA 10/2013 - 09/2011
2	Phosphatidylinositol 3-Kinase (1 Phosphatidylinositol 3 Kinase)IBA 01/2013 - 08/2010
2	Prostaglandin-Endoperoxide Synthases (Cyclooxygenase)IBA 09/2011 - 04/2009
2	Mitogen-Activated Protein Kinase Kinases (MEKs)IBA 06/2011 - 11/2007
2	daidzeinIBA 04/2011 - 11/2007
2	FlavonoidsIBA 12/2010 - 08/2010
2	kaempferolIBA 12/2010 - 08/2010
2	myricetinIBA 02/2009 - 07/2008
2	Sildenafil Citrate (Viagra)FDA Link 01/2005 - 09/2003
1	dostarlimabIBA 01/2022
1	daratumumabIBA 01/2021
1	thiamine triphosphorate (TTP)IBA 01/2021
1	isatuximabIBA 01/2021
1	Glycoproteins (Glycoprotein)IBA 01/2021
1	tislelizumabIBA 01/2020
1	Immune Checkpoint InhibitorsIBA 01/2020
1	Immune Checkpoint ProteinsIBA 03/2019
1	IpilimumabIBA 03/2019
1	pembrolizumabIBA 03/2019
1	cemiplimabIBA 03/2019
1	CTLA-4 AntigenIBA 03/2019
1	NivolumabIBA 03/2019
1	orobolIBA 01/2019
1	Casein Kinase 1 epsilonIBA 01/2019
1	LipidsIBA 01/2019
1	EnzymesIBA 01/2019
1	belimumabIBA 01/2018
1	osajinIBA 11/2017
1	golimumab FDA Link 01/2017
1	Infliximab (Remicade)FDA Link 01/2017
1	Certolizumab Pegol FDA Link 01/2017
1	Adalimumab (Humira)FDA Link 01/2017
1	AntigensIBA 10/2016
1	p38 Mitogen-Activated Protein KinasesIBA 03/2016
1	bakuchiolIBA 03/2016
1	JNK Mitogen-Activated Protein KinasesIBA 08/2014
1	3,6-dihydroxyflavoneIBA 08/2014
1	Therapeutic UsesIBA 08/2014
1	Peroxisome Proliferator-Activated Receptors (PPAR)IBA 08/2014
1	quercetagetinIBA 01/2013
1	Protein Serine-Threonine Kinases (Protein-Serine-Threonine Kinase)IBA 09/2011
1	CarcinogensIBA 07/2011
1	Epoxy Compounds (Epoxides)IBA 07/2011
1	Benzo(a)pyreneIBA 07/2011

Therapy/Procedure

6	Therapeutics 03/2022 - 01/2013
4	Immunotherapy 01/2022 - 10/2016
1	Intravenous Injections 10/2013
1	Oral Administration 10/2013